Wedmont Private Capital Sells 546 Shares of Zoetis Inc. $ZTS

Wedmont Private Capital cut its holdings in Zoetis Inc. (NYSE:ZTS) by 21.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,017 shares of the company’s stock after selling 546 shares during the quarter. Wedmont Private Capital’s holdings in Zoetis were worth $319,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ZTS. Brighton Jones LLC lifted its holdings in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the period. Waverly Advisors LLC bought a new position in shares of Zoetis during the 4th quarter valued at $494,000. Focus Partners Advisor Solutions LLC lifted its holdings in shares of Zoetis by 39.0% during the 4th quarter. Focus Partners Advisor Solutions LLC now owns 2,736 shares of the company’s stock valued at $446,000 after buying an additional 768 shares during the period. Vise Technologies Inc. lifted its holdings in shares of Zoetis by 64.1% during the 4th quarter. Vise Technologies Inc. now owns 5,602 shares of the company’s stock valued at $913,000 after buying an additional 2,189 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in shares of Zoetis during the 4th quarter valued at $1,780,000. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Down 0.9%

Shares of Zoetis stock opened at $145.82 on Monday. The firm has a market cap of $64.63 billion, a price-to-earnings ratio of 25.10, a PEG ratio of 2.34 and a beta of 0.88. The business has a 50-day moving average price of $151.25 and a 200-day moving average price of $156.45. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $197.51.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same quarter last year, the business posted $1.56 earnings per share. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on ZTS. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and reduced their price target for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Argus reiterated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Zoetis has an average rating of “Moderate Buy” and an average target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.